FDA sees bowel risk in early Glaxo vaccine data

WASHINGTON Wed Sep 22, 2010 9:11pm IST

Related Topics

Stocks

   

WASHINGTON (Reuters) - GlaxoSmithKline Plc's rotavirus vaccine may be linked to a small increase in a life-threatening type of bowel obstruction, U.S. health officials said on Wednesday.

Early data from a study in Mexico suggested infants given the Rotarix vaccine may face a higher chance of an intestinal problem known as intussusception in the 31 days after their first dose, the Food and Drug Administration said on its website.

"Although the results are preliminary and will require further evaluation, FDA approved revised labeling to inform healthcare providers of this finding," the agency said.

Rotavirus is the world's leading cause of severe diarrhea and dehydration in young infants. The benefits of rotavirus vaccines continue to outweigh risks, the FDA said.

Glaxo's rotavirus vaccine sales in 2009 were $440 million globally, including $118 million in the United States.

The British drug company's shares slipped 0.7 percent to $40.06 in morning trading on the New York Stock Exchange.

(Reporting by Lisa Richwine; Editing by Maureen Bavdek)

FILED UNDER:
  • Most Popular
  • Most Shared
Biotech Leap

Biotech Leap

World's top drugmaker Novartis takes aim at tech  Full Article 

Bird Flu

Bird Flu

Bird flu found in UK, Netherlands but authorities say little risk to humans  Full Article 

Drug Abuse

Drug Abuse

‘Tweens’ most likely to misuse over-the-counter meds.  Full Article 

Nutrition Value

Nutrition Value

School lunches may be better than lunch packed at home.  Full Article 

Smoking Problem

Smoking Problem

U.S. youth smoking, increased use of e-cigarettes a worry: CDC.  Full Article 

No Progress

No Progress

Progress on eliminating measles has stalled, WHO warns.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage